Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12790507 | 0.94 | TBXAS1 (0.52) | TBXAS1SMN1; SMN2HTTMAPK1TBXA2R | |
| SCHEMBL10820623 | 0.94 | TBXAS1 (0.52) | TBXAS1SMN1; SMN2HTTMAPK1TBXA2R | |
| SCHEMBL22694998 | 0.93 | TBXAS1 (0.46) | TBXAS1SMN1; SMN2HTTMAPK1TBXA2R | |
| SCHEMBL22694999 | 0.89 | TBXAS1 (0.44) | TBXAS1SMN1; SMN2HTTMAPK1TBXA2R | |
| SCHEMBL22694995 | 0.89 | TLR2 (0.45) | TBXAS1SMN1; SMN2HTTMAPK1TBXA2R | |
| SCHEMBL22694959 | 0.88 | TBXAS1 (0.48) | TBXAS1SMN1; SMN2HTTMAPK1TBXA2R | |
| SCHEMBL47381 | 0.87 | TBXAS1 (0.58) | TBXAS1SMN1; SMN2HTTMAPK1TBXA2R | |
| SCHEMBL13755880 | 0.87 | TBXAS1 (0.52) | TBXAS1SMN1; SMN2HTTMAPK1TBXA2R | |
| SCHEMBL23845953 | 0.87 | TLR2 (0.49) | TBXAS1SMN1; SMN2HTTMAPK1TBXA2R | |
| SCHEMBL25747574 | 0.86 | TBXAS1 (0.44) | TBXAS1SMN1; SMN2HTTMAPK1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009657-A1 | AMINE-CONTAINING LIPIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009657-A1 | AMINE-CONTAINING LIPIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-01-14 | — | — | US | disclosed |
| US-9006487-B2 | Amine-containing lipids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006487-B2 | Amine-containing lipids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-04-14 | — | — | US | disclosed |
| EP-2476756-A1 | Amine-containing lipids and uses thereof | Massachusetts Institute of Technology (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| WO-2009097332-A2 | THERAPEUTIC COMPOSITIONS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052673-A1 | THERAPEUTIC COMPOSITIONS | PHOSPHO1, SGMS1, APOB | TBXAS1 1849/4885SMN1; SMN2 490/4885HTT 2441/4885 |
| US-20110009641-A1 | Amine-containing lipids and uses thereof | PHOSPHO1, CHMP4B, SGMS1 | TBXAS1 2547/4885SMN1; SMN2 1726/4885HTT 1524/4885 |
| US-20160009657-A1 | AMINE-CONTAINING LIPIDS AND USES THEREOF | PHOSPHO1, CHMP4B, SGMS1 | TBXAS1 2547/4885SMN1; SMN2 1726/4885HTT 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.